THE ECONOMIC AND HUMANISTIC BURDEN OF PULMONARY ARTERIAL HYPERTENSION IN OMAN
Author(s)
Nada Abaza, BPharm1, Nasser Al Busaidi, MSc2, Baher Elezbawy, MPH, PhD3, Arif Al Bulushi, MBBS4, Abdel Rahman Elrashedy, BPharm5, Amr Nasrallah, MBA6, Mohamed Hossameldin, MBA5, Hady Mostafa, BPharm5, Suha Al Lawati, MSc7, Said Wani, BSc, MSc8, Ahmed Shalaby, MBA1, Sherif Attia Abaza, MBA1.
1Syreon Middle East, Cairo, Egypt, 2Department of Pulmonology, The Royal Hospital, Ministry of Health, Muscat, Oman, Muscat, Oman, 3Health Economist, Syreon Middle East, Alexandria, Egypt, 4Department of Adult Cardiology, National Heart Center, The Royal Hospital, Ministry of Health, Muscat, Muscat, Oman, 5Janssen Pharmaceutical Companies of Johnson and Johnson, Dubai, United Arab Emirates, 6Johnson & Johnson, Dubai, United Arab Emirates, 7Directorate General of Medical Supplies, Muscat, Oman, Muscat, Oman, 8Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary, Budapest, Hungary.
1Syreon Middle East, Cairo, Egypt, 2Department of Pulmonology, The Royal Hospital, Ministry of Health, Muscat, Oman, Muscat, Oman, 3Health Economist, Syreon Middle East, Alexandria, Egypt, 4Department of Adult Cardiology, National Heart Center, The Royal Hospital, Ministry of Health, Muscat, Muscat, Oman, 5Janssen Pharmaceutical Companies of Johnson and Johnson, Dubai, United Arab Emirates, 6Johnson & Johnson, Dubai, United Arab Emirates, 7Directorate General of Medical Supplies, Muscat, Oman, Muscat, Oman, 8Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary, Budapest, Hungary.
OBJECTIVES: This study aimed to estimate the 2025 economic and humanistic burden of pulmonary arterial hypertension (PAH) among adults in Oman, stratified by World Health Organization functional class (WHO-FC).
METHODS: A burden-of-disease model estimated direct medical costs, indirect costs, survival, and disability-adjusted life-years (DALYs) from healthcare-system and societal perspectives. Inputs were derived from published literature, local healthcare resource use, unit costs, and structured clinical expert interviews. Direct medical costs reflected healthcare resource utilization, while indirect costs captured productivity losses among patients and caregivers. Patients were grouped as WHO-FC I/II, III, or IV.
RESULTS: The estimated adult PAH population in Oman was 110 patients: 41% in FC I/II, 50% in FC III, and 9% in FC IV. Annual direct medical cost per patient was OMR 7,753 in FC I/II, OMR 10,978 in FC III, and OMR 39,425 in FC IV. Total annual direct medical cost was OMR 1.3 million, representing 0.129% of national healthcare expenditure. Indirect costs for patients and caregivers were estimated at OMR 935,967, with annual productivity losses of 32 days per patient in FC I/II and 202 days in FC III/IV. The total annual economic burden was estimated at 2.3 million OMR. Mean survival from diagnosis was 12.64 years in FC I/II, 7.66 years in FC III and 3.26 years in FC IV. DALYs lost per patient ranged from 34.41 in FC I/II to 43.84 in FC IV, with 4,151 DALYs lost across the adult PAH population.
CONCLUSIONS: PAH imposes a substantial socioeconomic burden, particularly in advanced disease stages. Direct costs in FC IV were 3.6-fold higher than in FC III, and costs in FC III were 1.4-fold higher than in FC I/II, indicating greater resource use with increasing severity. These findings support earlier diagnosis, optimized guideline-based care, and better planning of PAH services and caregiver support.
METHODS: A burden-of-disease model estimated direct medical costs, indirect costs, survival, and disability-adjusted life-years (DALYs) from healthcare-system and societal perspectives. Inputs were derived from published literature, local healthcare resource use, unit costs, and structured clinical expert interviews. Direct medical costs reflected healthcare resource utilization, while indirect costs captured productivity losses among patients and caregivers. Patients were grouped as WHO-FC I/II, III, or IV.
RESULTS: The estimated adult PAH population in Oman was 110 patients: 41% in FC I/II, 50% in FC III, and 9% in FC IV. Annual direct medical cost per patient was OMR 7,753 in FC I/II, OMR 10,978 in FC III, and OMR 39,425 in FC IV. Total annual direct medical cost was OMR 1.3 million, representing 0.129% of national healthcare expenditure. Indirect costs for patients and caregivers were estimated at OMR 935,967, with annual productivity losses of 32 days per patient in FC I/II and 202 days in FC III/IV. The total annual economic burden was estimated at 2.3 million OMR. Mean survival from diagnosis was 12.64 years in FC I/II, 7.66 years in FC III and 3.26 years in FC IV. DALYs lost per patient ranged from 34.41 in FC I/II to 43.84 in FC IV, with 4,151 DALYs lost across the adult PAH population.
CONCLUSIONS: PAH imposes a substantial socioeconomic burden, particularly in advanced disease stages. Direct costs in FC IV were 3.6-fold higher than in FC III, and costs in FC III were 1.4-fold higher than in FC I/II, indicating greater resource use with increasing severity. These findings support earlier diagnosis, optimized guideline-based care, and better planning of PAH services and caregiver support.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE311
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)